Clinigene International, a clinical research subsidiary of Biocon, and Pacific Biomarkers, a Seattle, Washington-based company, has announced a collaborative agreement to address the speciality biomarker and high-end clinical trial laboratory needs of the global pharmaceutical and biotech industry.
Biomarkers are traceable substance that is introduced into an organism as a means to examine its functions
Commenting on the partnership, Mr Peter Bains, Biocon's Director of Research Services Business, said, “Pacific Biomarkers is a recognised leader in providing speciality biomarkers and clinical diagnostic assay services to discovery and development-based life science enterprises. They have selected Clinigene as its partner in India and we look forward to supporting them in extending and expanding speciality services offering.”
“This partnership with Clinigene provides us access to India, an emerging hub for drug development and contract research,” said Mr Ronald Helm, CEO of Pacific Biomarkers.
Further, Clinigene is to offer to all its clients an economic option to conduct their biomarker and specialty clinical lab tests. “We expect to tap Clinigene's capabilities in cell-based assays and immuno-analytical testing services, which are of great interest to the global pharma and biotech community,” Mr Helm said.
anil.u@thehindu.co.in